Alzheimer’s Breakthrough Hinges on More Than Science
The Alzheimer’s research landscape is entering a new phase, as treatments that have taken decades to develop are finally reaching patients. However, pioneering researcher John Hardy emphasizes that getting these advances to people will depend on more than scientific progress alone. Alongside more effective drugs, better diagnosis and political will are still needed to improve treatment of Alzheimer’s disease. This shift in perspective is critical, as the current state of Alzheimer’s treatment is still far from ideal.
Hardy’s work in identifying the central role of amyloid in Alzheimer’s disease in the 1990s was instrumental in establishing the idea that deposits of amyloid form plaques around brain cells. These plaques are thought to disrupt normal brain function, increasing activity and triggering inflammatory responses. However, early approaches to treating Alzheimer’s did not yield the desired results, and it wasn’t until recent years that researchers developed drugs like Donanemab and Lecanemab that can remove amyloid deposits that have already formed from the brain.
The clinical trial of Lecanemab, results of which were published in 2022, showed for the first time that a drug could slow cognitive decline in people with Alzheimer’s disease. While this is a significant breakthrough, Hardy notes that it hasn’t stopped the disease, but rather slowed it. The prediction is that Lecanemab would slow the disease’s progression, increasing the time frame from around eight or nine years to about 11 or 12 years. This modest improvement highlights the need for continued scientific and political commitment to improving diagnosis and treatment.
Unpacking the Amyloid Theory and Its Implications
The amyloid theory is often debated, with some researchers arguing that focusing too heavily on it has slowed progress. However, most agree that amyloid plays a role, though how central it is remains contested. Hardy’s work has been instrumental in shaping our understanding of amyloid’s role in Alzheimer’s disease. His findings have led to the development of antibodies designed to prevent amyloid deposits from forming, and more recently, drugs like Donanemab and Lecanemab that can remove existing deposits.
However, the operational mechanics of these treatments are complex, and the decision-making logic behind their development is multifaceted. The fact that Lecanemab has been approved by the FDA and is available on Medicare in the US, while only private patients can access it in the UK, highlights the need for better diagnosis and investment in dementia services. The lack of access to these treatments for many patients underscores the need for political change and investment in dementia services.
The amyloid theory has also been criticized for being overly simplistic, and some researchers argue that it has diverted attention away from other potential causes of Alzheimer’s disease. However, Hardy’s work has shown that amyloid plays a critical role in the disease’s progression, and that removing existing deposits can slow cognitive decline. The ongoing debate surrounding the amyloid theory highlights the need for continued research and a more nuanced understanding of the disease’s underlying mechanisms.
Who Wins, Who Loses, and Who Gets Disrupted?
The development of treatments like Lecanemab and Donanemab has significant implications for the pharmaceutical industry, healthcare systems, and patients. Companies that have invested heavily in Alzheimer’s research, such as Eli Lilly and Biogen, stand to benefit from the approval and commercialization of these treatments. However, the high cost of these treatments and limited access to them will likely disrupt the healthcare landscape, particularly in countries with publicly-funded healthcare systems.
Patients who have access to these treatments will likely see improved outcomes, but those who do not will be left behind. The lack of access to these treatments highlights the need for better diagnosis and investment in dementia services. The development of these treatments also raises questions about the role of private companies in healthcare and the need for more equitable access to life-saving treatments.
The impact of these treatments on the broader healthcare landscape will be significant, particularly in terms of the economic burden of Alzheimer’s disease. The development of effective treatments will likely reduce the economic burden of the disease, but the high cost of these treatments will also increase healthcare costs. The need for better diagnosis and investment in dementia services will be critical in mitigating the economic impact of these treatments.
Steel-Manning the Skeptical Case
While the development of treatments like Lecanemab and Donanemab is a significant breakthrough, there are still many challenges ahead. The high cost of these treatments, limited access to them, and the need for better diagnosis and investment in dementia services all pose significant challenges. The skeptical case is that these treatments will not be widely adopted, and that the healthcare landscape will not be significantly disrupted.
However, this skeptical case assumes that the current state of Alzheimer’s treatment is acceptable, and that the status quo will be maintained. The development of effective treatments like Lecanemab and Donanemab challenges this assumption, and highlights the need for continued innovation and investment in dementia research. The skeptical case also assumes that the economic burden of Alzheimer’s disease will not be significantly impacted by the development of these treatments.
What’s Next?
The next verifiable event or milestone to watch will be the development of more efficacious versions of these drugs, as well as improvements in diagnosis and investment in dementia services. The FDA’s approval of Lecanemab and its availability on Medicare in the US will likely drive further investment in Alzheimer’s research and the development of new treatments. The development of biomarkers for Alzheimer’s disease, which can be used to diagnose the disease earlier and more accurately, will also be critical in improving treatment outcomes.
The development of these treatments will likely be a major focus of Alzheimer’s research in the coming years, and will require significant investment and innovation. The impact of these treatments on the healthcare landscape will be significant, and will require careful consideration of the economic and social implications of their development and adoption.
Pick one tactic from this post and apply it today. Which one will you start with?
By Daniel Cross, Digital Growth Strategist at TrendFlashy
Ready to launch your own asset?
Check out our guide on Building a Profitable Online Business.
